No Data
No Data
Express News | Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for Ta-Tma Under an Expanded Access Program
Institutions Own 43% of Omeros Corporation (NASDAQ:OMER) Shares but Retail Investors Control 53% of the Company
New Analysis of Omeros' Narsoplimab to Treat Complications From Stem Cell Transplant Support Results
Omeros Analyst Ratings
Omeros Announces Update on Statistical Analysis of Narsoplimab Primary Endpoint
Meros Announces Sensitivity Results For Narsoplimab In TA-TMA Patients, Confirming Over 3-Fold Mortality Risk Reduction; Primary Endpoint Met. BLA Resubmission To FDA This Quarter, MAA Submission In Europe By Mid-Year.